BioNTech SE (BNTX) Depreciation & Amortization (CF) (2018 - 2025)

BioNTech SE has disclosed Depreciation & Amortization (CF) across 8 years of filings, most recently posting $57.7 million for Q2 2025.

• Depreciation & Amortization (CF) for Q2 2025 came in at $57.7 million, up 7.43% year-over-year; the trailing twelve-month figure through Dec 2025 was $102.8 million (down 67.98% YoY), and the FY2024 annual result was $318.4 million, up 61.38% from the prior year.
• Depreciation & Amortization (CF) came in at $57.7 million for Q2 2025 at BioNTech SE, up from $45.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $176.7 million in Q4 2024 to a low of $15.68 in Q1 2021.
• The 5-year median for Depreciation & Amortization (CF) is $38.5 million (2022), against an average of $47.7 million.
• Peak annual rise in Depreciation & Amortization (CF) reached 199570464.14% in 2021, while the deepest fall reached 100.0% in 2021.
• BioNTech SE's Depreciation & Amortization (CF) stood at $29.7 million in 2021, then slipped by 0.52% to $29.6 million in 2022, then jumped by 186.56% to $84.8 million in 2023, then jumped by 108.47% to $176.7 million in 2024, then slumped by 67.34% to $57.7 million in 2025.
• The last three Depreciation & Amortization (CF) figures came in at $57.7 million (Q2 2025), $45.0 million (Q1 2025), and $176.7 million (Q4 2024), per Business Quant data.